Seeing Medicines, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Seeing Medicines, Inc. - overview
Established
2020
Location
Arden, NC, US
Primary Industry
Biotechnology
About
Based in North Carolina, US, and founded in 2020, Seeing Medicines, Inc. develops regenerative medicine treatments to restore and maintain vision in people with macular degenerative diseases. Leroux Jooste is the CEO and President of the company as of 2021. In June 2021, the company raised nearly USD 7 million in equity funding from three investors.
The company is developing novel cellular therapeutics to treat AMD (Age-related Macular Degeneration), Best Disease, Stargardt Disease, and other macular degenerative illnesses. SMI-001, a comprehensive therapy system for macular degeneration illnesses, is the company's flagship product. Seeing Medicines, Inc. plans to use the equity funding raised in June 2021 to help people with macular degeneration.
Current Investors
Sante Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Optometrists & Opticians Products and Services, Pharmaceutical Research & Development
Website
www.seeingmedicines.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.